Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Scientific Advisory Board
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology platform
Allosteric modulation
Our capabilities
Screening Assays
Chemistry
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
05.18
2023
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
05.11
2023
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
05.10
2023
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study
05.05
2023
Addex Convenes Annual General Meeting 2023
05.04
2023
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
04.05
2023
Addex Completes $5.0 Million Equity Financing
04.04
2023
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease
04.03
2023
Addex Raises $5.0 Million in Equity Financing
03.30
2023
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
03.28
2023
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
03.16
2023
Addex Announces Upcoming Conferences it will participate for H1 2023
02.09
2023
Addex Regains Nasdaq Listing Compliance
02.06
2023
Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
01.19
2023
Addex Provides Corporate Update and Financial Guidance
12.08
2022
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
11.11
2022
Addex Reports Q3 2022 Financial Results and Provides Corporate Update
11.03
2022
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
11.03
2022
Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
11.01
2022
Addex Increases Issued Share Capital to Create Treasury Shares
09.20
2022
Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
08.18
2022
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
08.15
2022
Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
08.12
2022
Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
07.26
2022
Addex Completes $4.2 Million Equity Financing
07.22
2022
Addex Raises $4.2 million in Equity Financing
07.21
2022
Addex Provides Corporate Update and Financial Guidance
07.21
2022
Addex Completes Reduction in Nominal Value of Shares
06.17
2022
Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
05.27
2022
Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
05.19
2022
Addex Announces Participation in the H.C. Wainwright Global Investment Conference
05.13
2022
Addex Announces Participation in the 22nd Bio€quity Europe Conference
05.10
2022
Addex Shareholders Approve All Resolutions at Annual General Meeting
05.05
2022
Addex Reports Q1 2022 Financial Results
04.28
2022
Addex to Present at the Swiss Biotech Day 2022
04.25
2022
Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference
04.13
2022
Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study
04.06
2022
Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders
03.31
2022
ADDEX CONVENES ANNUAL GENERAL MEETING 2022
03.24
2022
Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences
03.10
2022
Addex Reports Full Year 2021 Financial Results and Provides Corporate Update
03.07
2022
Addex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10, 2022
02.24
2022
Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums
02.03
2022
Addex Increases Issued Share Capital to Create Treasury Shares
01.11
2022
Addex to Present at the Swiss Equities Baader Virtual Conference
01.06
2022
Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
12.17
2021
Addex Raises $10.0 Million in Equity Financing
12.15
2021
Addex Provides Year End Pipeline Development Update
11.18
2021
Addex to Present at the Virtual German Equity Forum
11.15
2021
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
11.15
2021
Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
11.04
2021
Addex Reports Q3 2021 Financial Results and Provides Corporate Update
11.01
2021
Addex Therapeutics to Release Q3 2021 Financial Results and Host Conference Call on November 4, 2021
10.06
2021
Addex to Present at the Investors’ Day hosted by Voxia Communication
10.04
2021
Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors
09.29
2021
Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm
09.29
2021
Addex to Present at the Cantor Global Healthcare 2021 Conference
09.22
2021
CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A
09.08
2021
Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09.02
2021
Addex to Present at the Swiss Biotech Day
08.05
2021
Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update
08.02
2021
Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science
08.02
2021
Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021
07.29
2021
Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
07.07
2021
Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
07.01
2021
Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
06.30
2021
Addex Establishes At-The-Market ADS Equity Sale Program
06.29
2021
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
06.17
2021
Addex Shareholders Approve All Resolutions at Annual General Meeting
06.07
2021
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
05.24
2021
Addex to Participate at the Benchmark Company Healthcare House Call Conference
05.17
2021
Addex’s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
05.14
2021
Addex Convenes Annual General Meeting 2021
05.05
2021
Addex Reports Q1 2021 Financial Results and Provides Corporate Update
05.03
2021
Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021
04.26
2021
Addex Increases Issued Share Capital to Create Treasury Shares
04.26
2021
Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum
04.13
2021
Addex to Present at the 20th Annual Needham Virtual Healthcare Conference
04.08
2021
Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission
03.11
2021
Addex Reports Full Year 2020 Financial Results and Provides Corporate Update
03.09
2021
Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021
03.04
2021
Addex to Present at the H.C. Wainwright Global Life Sciences Conference
02.17
2021
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million
02.16
2021
Addex GABAB Positive Allosteric Modulators Demonstrate Promise in Alcohol Use Disorder
01.21
2021
Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy
01.12
2021
Addex to Present at the Baader Helvea Swiss Equities Conference
01.11
2021
Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities
01.07
2021
Addex Announces Pricing of $10.0 Million Global Offering
12.14
2020
Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities
11.03
2020
Addex Reports Q3 2020 Financial Results and Provides Corporate Update
11.02
2020
Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration
11.02
2020
Addex to Report Q3 Financial Results and host Conference Call on November 3, 2020
09.23
2020
Addex to Present at the Investora Conference
09.14
2020
Addex Therapeutics to Participate at the H.C. Wainwright 22nd Annual Global Investment Conference
08.31
2020
Addex Therapeutics to Participate at the Biotechgate Digital Partnering Conference
08.27
2020
Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist Using Computational Modelling
08.12
2020
Addex Reports 2020 Half-Year Financial Results and Provides Corporate Update
08.10
2020
ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2020 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 12, 2020
08.06
2020
Addex Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2020
07.20
2020
Van Leeuwenhoeck Issues Updated Addex Equity Research Report
06.16
2020
Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study
06.10
2020
Addex Shareholders Approve All Resolutions at Annual General Meeting
05.20
2020
Addex Reports Q1 2020 Financial Results and Provides Corporate Update
05.19
2020
Addex Therapeutics Establishes Scientific Advisory Board
04.08
2020
Addex Reports 2019 Full Year Audited Results and Provides Corporate Update
04.06
2020
Addex Therapeutics to Report 2019 Full Year Audited Results on April 8, 2020
03.18
2020
Addex Therapeutics Delays Start of Dipraglurant Pivotal Study and Reporting 2019 Full Year Audited Results
03.13
2020
Addex Therapeutics to Report 2019 Full Year Audited Results on March 19, 2020
03.03
2020
Addex Therapeutics Appoints Prominent Neuroscience Drug Developer Darryle D. Schoepp PhD as Chairman of its Scientific Advisory Board
02.26
2020
Addex Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
02.03
2020
Addex Therapeutics to Ring the Nasdaq Stock Market Closing Bell
01.29
2020
Addex Starts Trading American Depositary Shares on Nasdaq Under Ticker ADXN
01.13
2020
Addex Provides Trading Update and Completes 2019 with Cash Position of CHF31.5 million
01.08
2020
Addex to Attend 38th Annual J.P. Morgan Healthcare Conference
12.20
2019
Addex to Receive Additional $800K Funding from Indivior for GABAB PAM Addiction Program
12.18
2019
ADDEX THERAPEUTICS PUBLICLY FILES REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSs REPRESENTING SHARES
12.03
2019
Addex: Van Leeuwenhoeck Issues Update Equity Research Report
11.13
2019
Addex to Attend Jefferies 2019 London Healthcare Conference
11.08
2019
Addex to Present at 25th Annual BIO-Europe Conference in Hamburg
10.08
2019
Addex to Receive Additional Funding from Indivior for GABAB PAM Addiction Program
09.30
2019
Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update
09.25
2019
ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON SEPTEMBER 30, 2019
09.24
2019
ADDEX THERAPEUTICS SUBMITS REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSS REPRESENTING SHARES
08.27
2019
Van Leeuwenhoeck Issues Equity Research Report with Strong Buy and Price Target of CHF11-12 per Share
07.09
2019
Addex-Led Consortium Receives €4.85 Million Eurostars Grant to Develop Novel Allosteric Modulator to Treat Post-Traumatic Stress Disorder (PTSD)
06.20
2019
Addex Shareholders Approve All Resolutions at Annual General Meeting
05.28
2019
Addex Annual General Meeting Scheduled for June 19, 2019
05.20
2019
Addex Increases Issued Share Capital and Creates Treasury Shares
05.08
2019
Addex to Present at the 28th Medtech Investing Europe Conference
05.06
2019
Addex to Present During the Swiss Biotech Day
04.30
2019
ADDEX REPORTS 2018 FULL YEAR AUDITED RESULTS AND PROVIDES CORPORATE UPDATE
04.29
2019
Addex to Announce 2018 Full Year Audited Results on April 30, 2019
03.21
2019
Addex to Participate in the BIOEurope Spring Conference
03.11
2019
Addex to Present at the Cowen 39th Annual Health Care Conference on March 13, 2019
03.08
2019
Addex Trading Update in Accordance with Art. 53 of the SIX Listing Rules (Ad hoc publicity)
02.14
2019
Addex and Indivior to Accelerate Additional GABAB PAM Compounds for Addiction as Indivior Elects to Stop Development of ADX71441
01.07
2019
Addex Trading Update: Completes 2018 with Strong Cash Position
11.22
2018
Addex Van Leeuwenhoeck Equity Research Report Highlights Deep Pipeline Well Funded through Pivotal Registration Study and Increases Price Target to CHF 14
11.12
2018
Addex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference
10.22
2018
Addex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy
10.02
2018
Addex to Present at the Sachs 18th Annual Biotech in Europe Forum
09.28
2018
Addex Reports 2018 Half-Year Financial Results and Provides Corporate Update
09.25
2018
Addex to Present at the Investora Zurich Conference on 27 September
09.25
2018
ADDEX THERAPEUTICS RECOGNISED IN FINAL SHORTLIST FOR DEAL OF THE YEAR AT LIFESTARS AWARDS LIFE SCIENCE AWARDS FOR PARTNERSHIP WITH INDIVIOR
09.20
2018
Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the Tools for Human Drug and Brain Research (THuNDR2) Initiative from the Wellcome Trust
09.04
2018
Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD
07.12
2018
Van Leeuwenhoeck Issues Equity Research Note Highlighting Addex Investment Opportunity
06.21
2018
Addex Shareholders Approve All Resolutions at Annual General Meeting
04.30
2018
Addex Reports 2017 Full Year Results and Provides Corporate Update
03.29
2018
Addex Sucessfully Raises CHF40 million in Capital Increase
03.20
2018
Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association
03.19
2018
Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting
03.05
2018
Addex Secures Investor Commitment for CHF40 million Capital Increase Following Successful Completion of Book Building Process
02.23
2018
Addex Publishes Extraordinary General Meeting Invitation
02.15
2018
Addex Launches CHF40 million Capital Increase with Commitments from Specialist US Healthcare Investors
02.07
2018
Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management
02.05
2018
Addex Provides Key Financial Indicators and Trading Update
02.02
2018
Van Leeuwenhoeck Issues Equity Research Note Highlighting Value of Recent Indivior Strategic Partnership on GABAB PAM
01.08
2018
Addex Therapeutics Equity Research Report Update Issued by valuationLAB
01.03
2018
Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments
10.18
2017
Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share
10.03
2017
Addex Therapeutics ADX71441 Program Awarded $5.3 Million Grant from US National Institute on Drug Abuse to Support Human Studies for the Treatment of Cocaine Use Disorder
09.26
2017
Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results
09.18
2017
Addex Makes Changes to Executive Management
06.23
2017
Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting
06.06
2017
Addex Annual General Meeting Scheduled for 22 June 2017
05.31
2017
Addex Increases Issued Share Capital and Creates Treasury Shares
05.09
2017
Addex ADX71441 Demonstrates Preclinical Analgesic Effects
05.04
2017
Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology
04.05
2017
Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results
02.28
2017
Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018
02.27
2017
Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
02.06
2017
Addex’s Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases
01.31
2017
Addex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson’s Disease
01.09
2017
Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain
12.13
2016
Addex ADX71441 Pharmacological Profile Published in Neuropharmacology
11.28
2016
Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
10.17
2016
Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia
10.11
2016
Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction
09.30
2016
Addex Therapeutics Reports First Half 2016 Operating Highlights and Financial Results
09.20
2016
Addex Collaborators Published New Data Supporting the Role of Negative Allosteric Modulators of Follicle Stimulating Hormone and Luteinizing Hormone Receptors in Reproductive Health
07.27
2016
Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity.
07.20
2016
LifeSci Capital Issues Equity Research Report on Addex Therapeutics
06.24
2016
Addex Shareholders Approved all Board Proposals at 2016 Annual General Meeting
06.13
2016
Addex mGluR4 and mGluR7 Programs Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
06.09
2016
Addex ADX71441 Demonstrates Positive Results in Non-Human Primate Model of Cocaine Addiction
06.08
2016
Van Leeuwenhoeck Issues Research Note on Addex Therapeutics
06.02
2016
Addex Annual General Meeting Scheduled for 23 June 2016
06.02
2016
Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society
05.30
2016
Addex Increases Issued Share Capital and Creates Treasury Shares
04.29
2016
Addex Therapeutics Reports 2015 Financial Results
04.11
2016
Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
03.15
2016
Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
01.11
2016
Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept
01.04
2016
Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
12.17
2015
Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial
12.15
2015
Addex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuroprotective Agents
12.09
2015
Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis
12.07
2015
Addex Moves R&D Operations to Geneva’s Campus Biotech
11.25
2015
Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program
11.23
2015
Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases
11.19
2015
ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share
10.13
2015
Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder
09.30
2015
Addex Therapeutics Reports First Half 2015 Financial Results
09.23
2015
Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
09.08
2015
Pierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage Agreement in the Central Nervous System (CNS) Field
08.17
2015
Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics
08.14
2015
Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s Disease
08.05
2015
valuationLAB Issues Research Report on Addex Therapeutics
07.22
2015
Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation
06.12
2015
Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting
06.03
2015
Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain
05.29
2015
Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia
05.27
2015
Addex Annual General Meeting Scheduled for 11 June 2015
05.07
2015
Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia
04.30
2015
Addex Therapeutics Reports 2014 Financial Results
03.09
2015
Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017
02.23
2015
Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation
02.19
2015
Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death
01.19
2015
Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia
01.09
2015
Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update
01.07
2015
Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder
12.17
2014
Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000
10.21
2014
Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder
09.30
2014
Addex Therapeutics Reports First Half 2014 Financial Results
07.10
2014
Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
06.30
2014
Addex Shareholders Approve All Board Proposals at Annual General Meeting
06.12
2014
Addex Therapeutics Publishes Annual General Meeting Agenda
05.30
2014
Addex Therapeutics Publishes Annual Report 2013
04.30
2014
Addex Therapeutics Reports 2013 Financial Results
02.07
2014
Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms
11.04
2013
Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction
10.29
2013
Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
10.03
2013
Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease
09.17
2013
Addex Therapeutics First Half 2013 Financial Results
09.04
2013
Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1
08.09
2013
Addex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors
05.31
2013
Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down
05.28
2013
Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders
05.21
2013
Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441
05.02
2013
Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study
04.30
2013
Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role
04.30
2013
Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence
04.24
2013
Addex Receives Approval to Initiate a Phase 1, First–In-Man, Clinical Study for ADX71441
04.22
2013
Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant
04.18
2013
Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)
03.21
2013
Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)
03.20
2013
Addex Shareholders Approve All Board Proposals at Annual General Meeting
03.19
2013
Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research
03.04
2013
Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor
02.28
2013
Addex Therapeutics Reports 2012 Financial Results
02.07
2013
Addex to Focus Resources on Clinical Pipeline
01.29
2013
Addex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia
01.22
2013
Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441
01.07
2013
Addex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease
12.20
2012
Addex Scientists Discover and Characterize the First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 receptor
11.27
2012
Addex’ Dipraglurant Named as one of the “Top 10 Neuroscience Projects to Watch” by Windhover and Virginia Herndon
11.05
2012
Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients
10.29
2012
Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking
10.24
2012
Addex Updates Financial Guidance for 2012
10.12
2012
Addex Therapeutics raises $10 million in a Private Placement to International Institutional Investors
10.11
2012
Addex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 Meeting
10.02
2012
Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases
09.24
2012
Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model
09.17
2012
Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms
08.22
2012
Addex Therapeutics First Half 2012 Financial results
08.20
2012
Addex Therapeutics First Half 2012 Financial Results Next Wednesday
07.16
2012
Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson’s Disease Pre-Clinical Models
07.03
2012
Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research
06.18
2012
Addex to Present Phase 2a Dipraglurant Data at Movement Disorder Society’s International Congress
06.05
2012
Addex Partner to Initiate Phase 2 Clinical Trial of ADX71149 for the Treatment of Major Depressive Disorder with Anxiety Symptoms
05.09
2012
Addex Shareholders Approve All Board Proposals at Annual General Meeting
04.16
2012
Addex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder
04.13
2012
Addex Takes Steps to Rightsize Operations and Position the Company for Future Success
03.21
2012
Addex changes name to Addex Therapeutics
03.21
2012
Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
02.23
2012
Addex Pharmaceuticals Reports 2011 Financial Results
02.21
2012
Addex Pharmaceuticals 2011 Financial Results this Thursday
02.10
2012
Addex to present at the BIO CEO & Investor Conference
11.28
2011
Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors the addex allosteric modulator platform enabled breakthrough discovery, advancing the understanding of glp-1 mediated gpcr signaling
11.02
2011
Addex Presents Data on Allosteric Modulators of GPCRs at the Discovery on Target Conference
10.24
2011
Addex to Present at the BIO Investor Forum in San Francisco
10.19
2011
Addex to Present in NYC at the Newsmakers in the Biotech Industry conference hosted by BioCentury and Thomson Reuters
10.03
2011
Addex to Present Progress on Multiple Allosteric Modulator Programs for Neurodegenerative and other Neurological Disorders
09.26
2011
Addex to Present at the Jefferies 2011 Global Healthcare Conference in London
09.02
2011
Addex Regains Rights to Parkinson’s Drug Candidates from Merck
08.15
2011
Addex Pharmaceuticals Appoints Dr Bharatt Chowrira as CEO
08.11
2011
Addex Pharmaceuticals Announces Board Changes
07.27
2011
Addex Pharmaceuticals First Half 2011 Financial Results
07.20
2011
Addex Pharmaceuticals First Half Financial Results on July 27
07.07
2011
Addex Announces Corporate Reorganization and Restructuring Initiative to Strengthen Its Leadership Position in Allosteric Modulation-Based Drug Discovery and Development Focus on Core R&D Programs
06.03
2011
Addex Pharmaceuticals CEO Steps Down
04.28
2011
Addex Shareholders Appoint Hoyoung Huh and Oleg Nodelman to Board, Approve All Board Proposals at Annual General Meeting
03.31
2011
Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)
03.28
2011
Addex Partner Starting Clinical Schizophrenia Trial
03.14
2011
Addex Converts Mandatory Convertible Notes and Issues Ordinary Shares
03.09
2011
Addex Board Proposes Hoyoung Huh and Oleg Nodelman for Election to the Board of Directors
02.23
2011
Addex Pharmaceuticals 2010 Financial Results
02.18
2011
Addex Pharmaceuticals 2010 Financial Results Next Wednesday
12.10
2010
Addex Awarded EuropaBio’s Most Innovative SME Award
11.12
2010
Addex Highlights Strength of Allosteric Modulation Technology Platform with Multiple Presentations at Society for Neuroscience 2010
09.15
2010
Addex Pharmaceuticals Raises CHF20 Million from Biotechnology Value Fund
09.08
2010
Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to Treat Levodopa-Induced Dyskinesia in Parkinson’s
09.02
2010
Addex Drug Candidate Effective in Alzheimer’s Disease Model
08.25
2010
Addex Partner Completes ADX71149 Phase I Program
07.28
2010
Addex Pharmaceuticals First Half 2010 Financial Results
07.21
2010
Addex First Half 2010 Financial Results Next Wednesday
07.13
2010
Addex Drug Candidate Effective in Osteoarthritis Pain Model
06.15
2010
Addex’s ADX48621 Effective in Preclinical Parkinson’s Disease Studies
05.18
2010
Addex Executive Management Change
05.11
2010
Addex R&D Day Highlights
04.30
2010
Addex Shareholders Approve All Board Proposals at 2010 AGM
04.28
2010
Addex to Host R&D Day on May 11
02.23
2010
Addex Pharmaceuticals 2009 Financial Results
02.17
2010
Addex to Present at The New York Academy of Sciences
02.16
2010
Addex to Host 2009 Financial Results Call on Feb. 23
02.08
2010
Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models
12.15
2009
Development of ADX10059 Ended for Long-term Use
12.14
2009
Addex Ends Migraine Prevention Study
12.02
2009
Addex Extends Parkinson’s Disease Collaboration with Merck & Co., Inc.
11.24
2009
Addex ADX48621 Positive Primate Parkinson’s Data
11.16
2009
Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
11.03
2009
Addex Presents ADX10059 PD-LID Data at GPCR Drug Discovery Conference
09.28
2009
Addex completes enrollment of first mid-stage clinical GERD trial
09.17
2009
Laurent Massuyeau, Head of Business Development, Resigns
09.14
2009
Addex’ ADX10059 has potential for Parkinson’s disease levodopa induced dyskinesia (PD-LID)
07.28
2009
Addex Pharmaceuticals Reports First Half 2009 Financial Results
07.23
2009
Addex First Half 2009 Financial Results Tuesday, July 28
07.16
2009
Addex R&D Day Highlights Broadened Therapeutic Potential of Allosteric Modulation Platform to Include Cytokine Receptors as well as GPCRs
07.10
2009
Addex Achieves Second Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.
07.02
2009
Addex to Host R&D Day on July 16
06.24
2009
Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator novel approach has potential for treatment of multiple cns disorders
05.27
2009
Glutamate Receptor “mGluR5” Implicated in GERD
04.29
2009
Addex Presents Data on ADX10059 at the AAN
04.17
2009
Addex Shareholders Approve All Board Proposals at 2009 AGM
02.24
2009
Addex Pharmaceuticals 2008 Financial Results
02.17
2009
Addex 2008 Full Year Financial Results Next Tuesday
01.28
2009
Addex Successfully Completes ADX48621 Phase I Program
12.17
2008
Addex Starts a Second Phase IIb Trial of ADX10059 in GERD
12.17
2008
Addex Starts a Phase IIb Trial of ADX10059 for Migraine Prevention
12.02
2008
Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients
11.12
2008
GSK Reports Owning 5% of Addex
10.15
2008
Addex Parkinson’s Product Progressing in Early Clinical Trials
09.26
2008
GSK Reports Owning 3% of Addex
09.10
2008
Better Tolerated Formulation of ADX10059 Reduces Acid Reflux
08.07
2008
Disclosure of Shareholdings in Accordance with Stock Market Rules
08.05
2008
Disclosure of Shareholdings in Accordance with Stock Market Rules
07.28
2008
Addex Pharmaceuticals Reports First Half 2008 Financial Results, Maiden Profit
07.28
2008
Laurent Galibert Appointed Head of Inflammation Business Unit
07.18
2008
Addex First Half 2008 Financial Results Monday, July 28
06.04
2008
Addex Starts Phase I ADX10059 Interaction Study
05.27
2008
Disclosure of Shareholdings in Accordance with Stock Market Rules
04.24
2008
Addex Starts ADX10059 Phase I Formulation Selection Study
04.18
2008
Addex Appoints Laurent Massuyeau as Head of Business Development
04.18
2008
Addex Shareholders Elect Ray Hill to Board of Directors at the 2008 Annual General Meeting
03.28
2008
Addex Pharmaceuticals R&D Day on April 24
03.26
2008
Mark Epping-Jordan, Chief Scientific Officer, Resigns
03.17
2008
Disclosure of Shareholdings in Accordance with Stock Market Rules
02.26
2008
Addex Pharmaceuticals 2007 Financial Results
02.25
2008
Addex Achieves First Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.
01.03
2008
Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia
01.03
2008
Addex Announces ADX10059 Phase IIa Acute Anxiety Data
12.03
2007
Addex and Merck & Co. Collaborate to Develop Drugs for Parkinson’s Disease
11.29
2007
Addex Pharmaceuticals Confirms Extension of Major Shareholder Lock-up
10.29
2007
Addex Presents ADX10059 GERD Data at Conference
10.01
2007
ADX10061 Smoking Cessation Data
08.17
2007
Addex Pharmaceuticals appoints Head of ADME/PK
07.25
2007
Addex Pharmaceuticals First Half 2007 Financial Results
07.18
2007
Addex First Half 2007 Financial Results Next Wednesday
05.21
2007
Addex Prices IPO Shares at CHF73, raises CHF137 million
05.16
2007
Addex appoints Head of IR and Communications
05.09
2007
Addex Launches IPO on SWX Swiss Exchange
04.23
2007
Addex Pharmaceuticals Plans IPO on SWX Swiss Exchange
04.20
2007
Addex reports positive results in Phase IIa clinical trial with ADX10059 in Migraine
04.17
2007
Addex achieves statistically significant outcome in Phase IIa clinical trial with ADX10059 in Gastro-Esophageal Reflux Disease
04.10
2007
Addex initiates Phase I trials on ADX48621, a novel compound for treatment of Depression, Anxiety Disorder and Pain
01.24
2007
Addex starts Phase IIa Proof of Concept Study on ADX10061 for Smoking Cessation
12.19
2006
Addex begins Phase IIa Proof of Concept Study on ADX10059 for Treatment of Acute Anxiety
09.19
2006
Addex Pharmaceuticals Raises CHF40 million-SR One and Roche Venture Funds invest in Series C Private Financing
08.30
2006
Addex commences Phase II clinical trials programme with ADX10059
09.22
2005
Addex Pharmaceuticals Initiates Phase I Trials with ADX10059, a novel compound intended for Anxiety and Migraine
01.26
2005
Addex Pharmaceuticals named by tornado insider among europe's top 100 private tech companies
01.17
2005
Addex Pharmaceuticals enters into Collaboration with Ortho-McNeil Pharmaceutical to Develop Novel Treatments for Anxiety, Depression, Schizophrenia and Alzheimer's disease
11.11
2004
Addex Pharmaceuticals lauréate du Prix de la Jeune Industrie de Genève
05.17
2004
Addex Pharmaceuticals Completes Largest ever European Biotech Series B Fund Raising
12.10
2003
Addex Pharmaceuticals Signs Three year Clinical Development Partnership with Fulcrum Pharma Plc
12.18
2002
CeNeS Announces Phase II Drug Deal with Addex Pharmaceuticals
07.11
2002
Addex Pharmaceuticals Attracts Venture Funding From Leading European VC Firms
Back